Indivior (NASDAQ:INDV) Upgraded by RODMAN&RENSHAW to Strong-Buy Rating

Indivior (NASDAQ:INDV) was upgraded by stock analysts at RODMAN&RENSHAW to a “strong-buy” rating in a research report issued to clients and investors on Tuesday,Zacks.com reports.

INDV has been the subject of a number of other research reports. Craig Hallum dropped their price target on Indivior from $20.00 to $16.00 and set a “buy” rating for the company in a research report on Friday, October 11th. Rodman & Renshaw assumed coverage on shares of Indivior in a report on Tuesday. They set a “buy” rating and a $16.00 target price for the company. Finally, Piper Sandler reaffirmed an “overweight” rating and issued a $16.00 price target (up previously from $15.00) on shares of Indivior in a report on Friday, October 25th.

Indivior Price Performance

INDV opened at $12.22 on Tuesday. Indivior has a 1-year low of $7.33 and a 1-year high of $23.22. The stock has a market cap of $1.68 billion, a P/E ratio of -305.42 and a beta of 0.74. The stock’s 50 day simple moving average is $11.72 and its 200 day simple moving average is $11.01.

Institutional Trading of Indivior

Hedge funds and other institutional investors have recently added to or reduced their stakes in the stock. Iron Triangle Partners LP purchased a new position in Indivior in the 3rd quarter valued at about $8,243,000. Krensavage Asset Management LLC purchased a new position in shares of Indivior during the third quarter valued at approximately $6,843,000. Stonepine Capital Management LLC acquired a new stake in Indivior during the third quarter worth approximately $2,632,000. Clark Estates Inc. NY acquired a new stake in Indivior during the third quarter worth approximately $2,477,000. Finally, AlphaCentric Advisors LLC purchased a new stake in Indivior in the 3rd quarter worth approximately $2,364,000. Hedge funds and other institutional investors own 60.33% of the company’s stock.

Indivior Company Profile

Indivior PLC, together with its subsidiaries, engages in the development, manufacture, and sale of buprenorphine-based prescription drugs for the treatment of opioid dependence and co-occurring disorders in the United States, the United Kingdom, and internationally. The company develops medicines to treat substance use disorders, serious mental illnesses, and opioid overdose.